Expanding access to telehealth-based treatment programs that include medications for OUD, like buprenorphine or Sublocade, to patients as they leave custody can upend this cycle of incarceration through seamlessly following patients wherever they go next. The TREATS Act creates a legal pathway for this care to continue.
While communities should tailor their opioid settlement spending strategies to their local needs, we should embrace basic, population-focused prevention strategies. Prevention efforts can turn the tide of addiction for decades to come. And they are where we’ll get the biggest bang for our buck.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Patients with opioid use disorder are more likely to stick with their treatment plan when offered buprenorphine via telemedicine, according to a new study. The study involved 1,378 patients, and their 180-day treatment retention rate was 56.4%.
Preventing drug diversion starts with understanding the signs of a substance use disorder (SUD) in hospital and health system staff workers, those closest to the problem and one of the most affected parties.
I write this because of my own personal experience with stealing prescription drugs while employed as a nurse, which led to me serving a four-month jail sentence and losing the career of my dreams.
While telehealth has provided many benefits throughout the pandemic, it can be a lonely and sterile way of receiving treatment. Individuals experiencing substance use disorder who only receive treatment through telehealth may miss opportunities to connect with others in support of the recovery process.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A new Stanford study revealed that among Medicaid patients who had never taken an opioid, 30% developed an opioid dependency following their first prescription. The research showed that opioids that have historically marketed as "safe," such as tramadol, actually carry quite a high addiction risk for vulnerable populations.
Complementary and integrative healthcare providers, including chiropractic physicians, acupuncturists, and massage therapists, provide effective and safe treatments for pain. Yet, they are too often overlooked by Congress and a healthcare system that tends to default to pharmacological treatments as the first step in pain reduction.
Clinical drug testing gives physicians the ability to uncover potentially problematic drug use and preempt devastating outcomes. Physicians value these tests, but they also want clearer guidelines to optimize their use.
Startup experts and clinicians working on the front lines of the drug and overdose epidemic doubt the flashy Silicon Valley technology will ever reach people in the throes of addiction who are unstably housed, financially challenged, and on the wrong side of the digital divide.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Clinicians must be aware that coordination of care is one of the key factors to combat opioid epidemic and stop overuse of more powerful and dangerous medications.
Substance use support delivered virtually is accessible, cost-effective, and allows anyone struggling with substance use disorder to incorporate life-changing cognitive-behavioral tools into their daily habits.
In addition to monetary damages and the guilty pleas, the government is seeking to transform the maker of OxyContin into a public benefit company that would fund efforts to curb opioid abuse and give away drugs to prevent overdose deaths.
The legality of designed drugs must be addressed given the ease with which anyone can buy them and especially because of the addiction crisis we are currently experiencing.
American pharma companies — architects of the opioid crisis in the United States and avid hunters of new markets — stand at the ready to feed and fuel demand for painkillers in India where attitudes toward pain toleration have changed.